IDH1 and cholangiocarcinoma: While the efficacy of enasidenib in cholangiocarcinoma has not yet been evaluated, one possible therapeutic strategy to overcome mutant IDH1/2 isoform switching would be combination therapy with ivosidenib and enasidenib, or treatment with dual mutant IDH1/IDH2 inhibitors25.